Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

FDA Approves Johnson & Johnson Single-Dose Covid-19 Vaccine Shot For Use In The U.S

By John F. Heerdink, Jr.

As per reports, the Food & Drug Administration has given clearance to Johnson & Johnson (JNJ) Covid-19 one-shot vaccine giving the U.S its third vaccine to prevent the pandemic. Health officials have been waiting for a one-dose option instead of two to help fasten the vaccination drive, as the virus has already taken more than 510,000 lives in the U.S. and continues to increase at a worrying rate.

The FDA informed that J&J’s vaccine offers strong protection against hospitalizations, serious illness, and death. The dose proved to be 85% protective against the most severe COVID-19 illness, in a study that covered three continents including countries like South Africa, where the most severe variants are spreading. As of now, the vaccine has been authorized for emergency use in adults 18 and older, but the vaccine is still due to be tested in teens and pregnant women.

By month end, J&J expects to offer 20 million doses to the U.S., and 100 million by summer, and about 1 billion doses globally by the end of the year. The company is additionally seeking authorization for emergency use of its vaccine in Europe and from the World Health Organization. The island nation of Bahrain became the first to clear its use this week.

Johnson & Johnson is also testing two doses of its vaccine in a different study. Dr. Francis Collins, director of the National Institutes of Health informed if a second dose is studied to be better, people who got vaccinated earlier would be offered the second one.

In the U.S., the two-dose Pfizer and Moderna shots showed 95% protection against symptomatic COVID-19. J&J’s one-dose effectiveness showed 85% against severe COVID-19 cases and dropped to 66% when moderate cases were rolled in. However, the above studies, with the Pfizer and Moderna research finished before the new virus strain began spreading.

Health officials are planning to use the J&J vaccine in cases where it’s unsure that someone will come back for a second vaccination dose. The J&J vaccine is also easy to store in the refrigerator whereas, the Moderna and Pfizer require high temperatures to be stored.

Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.

If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus. 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive! Please join us at Vista Partners and receive our FREE email updates throughout the week and view our exclusive content and research.

(Read Original Story: J&J’s 1-dose shot cleared, giving US 3rd COVID-19 vaccine in AP News)


Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us